Venatorx Pharmaceuticals Announces Changes to Executive Leadership See more here
Read More
Venatorx Pharmaceuticals Expands Senior Leadership Team Key Hires in CMC/Technical Operations, Business Development, and Finance See more here
Read More
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam No Clinical Safety or Efficacy Issues Identified No Requirement for Further Clinical Data or Trials See more here
Read More
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint Composite Efficacy Sustained at Late Follow-up Visit Safety Profile Consistent with Meropenem See more here
Read More
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries See more here
Read More
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S. See more here
Read More
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis See more here
Read More
Venatorx Pharmaceuticals to Present at IDWeek 2023 - New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam - MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer See more here
Read More
Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults Cefepime-taniborbactam has also demonstrated in vitro activity against CDC Urgent and Serious Threat Pathogens carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa and Extended Spectrum Beta-lactamase-producing Enterobacterales In the…
Read More
Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US Growing Global Incidence of Carbapenem-Resistant Enterobacterales Metallo-beta-lactamases were the most frequently identified carbapenem resistance mechanism among Enterobacterales isolates in IHMA global surveillance See more here
Read More